Natixis Advisors
ANIK icon

Natixis Advisors’s Anika Therapeutics ANIK Stock Holding History

Natixis Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-179,666
Closed -$7.33M – 1308
2021
Q1 		$7.33M Buy
179,666
+10,603
+6% +$402K 0.04% 471
2020
Q4 		$7.65M Sell
169,063
-15,740
-9% -$597K 0.04% 427
2020
Q3 		$6.54M Buy
184,803
+2,715
+1% +$98.1K 0.04% 437
2020
Q2 		$6.87M Buy
182,088
+16,973
+10% +$559K 0.05% 409
2020
Q1 		$4.77M Buy
165,115
+1,081
+0.7% +$43.7K 0.04% 465
2019
Q4 		$8.51M Buy
164,034
+11,470
+8% +$666K 0.06% 355
2019
Q3 		$8.37M Sell
152,564
-4,995
-3% -$256K 0.07% 323
2019
Q2 		$6.4M Buy
157,559
+101,237
+180% +$3.69M 0.05% 385
2019
Q1 		$1.7M Sell
56,322
-68,658
-55% -$2.35M 0.01% 808
2018
Q4 		$4.2M Sell
124,980
-9,538
-7% -$344K 0.04% 459
2018
Q3 		$5.67M Buy
134,518
+1,842
+1% +$72.8K 0.05% 419
2018
Q2 		$4.25M Buy
132,676
+6,388
+5% +$263K 0.04% 519
2018
Q1 		$6.28M Buy
126,288
+6,835
+6% +$386K 0.06% 360
2017
Q4 		$6.44M Buy
119,453
+5,919
+5% +$328K 0.07% 344
2017
Q3 		$6.58M Buy
113,534
+22,225
+24% +$1.16M 0.07% 346
2017
Q2 		$4.5M Buy
91,309
+3,311
+4% +$152K 0.05% 465
2017
Q1 		$3.82M Buy
+87,998
New +$4.2M 0.04% 512

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's ANIK Position: Q2 2021 in Review

Natixis Advisors sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 179,666 shares — an estimated $7.33M sold.

Natixis Advisors first reported a position in ANIK in Q1 2017 and held it in 17 quarters. The position peaked at $8.51M in Q4 2019. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Natixis Advisors reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Natixis Advisors sold 179,666 Anika Therapeutics shares in Q2 2021, an estimated $7.33M.
  • Natixis Advisors first reported a position in Anika Therapeutics in Q1 2017 and held it in 17 quarters.
  • Natixis Advisors's Anika Therapeutics position peaked at $8.51M in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Natixis Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.